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Objectives. To investigate the effect of elevated serum homocysteine and haemostatic as well as clinical risk factors on the
tendency to restenosis after carotid artery thrombendarterectomy.
Design. A prospective, observational study.
Patients and methods. In the period from October 1999 to October 2002, 86 patients were subjected to 96 carotid
endarterectomies because of internal carotid artery stenoses. The carotid stenoses were symptomatic in 86 cases (90%).
Fasting plasma homocysteine, fibrinogen, D-dimer and activated protein C resistance were measured the day before surgery.
Follow-up was done 1, 3, 6, 12 and 18 months postoperatively and yearly thereafter with clinical assessment and triplex
ultrasonography. The median follow-up time was 17 months (range 9–42 months). Freedom from restenosis was estimated
with Kaplan–Meier curves, using log-rank test for comparison between groups. Variables found to be significantly related to
restenosis rates were included in a multivariate analysis performed with the Cox proportional hazards model. Comparison of
means of continuous data between two groups was done with Student’s t-test and more than two groups with one-way
analysis of variance.
Results. Restenoses within 12 months of the operation occurred in 11 cases (11%). Univariate analysis revealed that plasma
homocysteine values #10 mmol/l and freedom from ischaemic heart disease were both significantly associated with an
increased risk of restenosis (p ¼ 0.0076 and 0.0059). However, multivariate analysis showed that only plasma homocysteine
values ,10 mmol/l were independently and significantly associated with an increased risk of restenosis (p ¼ 0.046). There
were no associations between the degree of atherosclerotic affection of the precerebral circulation or symptoms on one hand
and the levels of homocysteine, fibrinogen, D-dimer and activated protein C resistance on the other.
Conclusion. There seems to be an independent, significant association between homocysteine values within the lower two
thirds of the normal range and restenosis after carotid endarterectomy. Studies on the biological properties of human
endothelial cells from different types of vasculature and different locations, specifically with respect to homocysteine
metabolism and its effect, are warranted.
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Introduction
The incidence of early (,12 months) restenoses after
endarterectomy of the internal carotid artery after
primary closure has been reported to vary between 0
and 21%.1 – 3 Patch closure of the arteriotomy has been
found to reduce the tendency to restenoses.2 Although
operative technique may be a cause of restenosis after
carotid endarterectomy, it has been suggested that
progression of atherosclerosis may also be a contri-
butor to this problem.4 The level of plasma homo-
cysteine has been demonstrated to be an independent
risk factor for peripheral vascular as well as coronary
atherosclerosis.5,6 A study of adults asymptomatic of
atherosclerosis revealed a significant relationship
between intimal-media carotid artery wall thickening
and homocysteine levels above 10.5 mmol/l.7 Another
study failed to demonstrate a significant relationship
between elevated homocysteine levels and the pro-
gression of known carotid artery atherosclerosis.8
Results of studies on the relationship between elevated
plasma homocysteine levels and tendency to rest-
enoses after cardiovascular or peripheral vascular
interventions are controversial.9 – 16 The aim of this
study is to investigate the relationship between early
restenoses after carotid endarterectomy and levels of
plasma homocysteine as well as haemostatic and
clinical risk factors possibly affecting patency rates.
Patients and Methods
From October 1999 to October 2002, 102 patients were
subjected to 112 carotid endarterectomies at our
institution because of internal carotid stenoses. Two
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patients suffered perioperative stroke and two patients
died within 30 days of surgery, leaving a combined
stroke-mortality rate of 3.6%
Operations were excluded from the study if patch
closure of the arteriotomy was applied (two oper-
ations, both on male patients), a residual stenosis was
identified at the first post-operative duplex ultrasound
(one operation), study blood tests not performed (five
operations), the patient either died or was lost to
follow up within 9 months of the operation (eight
operations). Thus the study included 86 patients
subjected to 96 internal carotid endarterectomies.
Preoperative assessment of extra cranial arteries
was done with triplex ultrasound supplemented with
a two plane digital subtraction angiography or MRI for
evaluation of the degree of stenosis, the extent of
atherosclerotic disease of the precerebral circulation as
well as the anatomy of the intracranial circulation.
Fasting values of plasma homocysteine (Hcy) (normal
range 0–15 mmol/l), fibrinogen (Fibr) (normal range
2 – 4 g/l), D-dimer (D-dim) (normal range 0.0 –
0.5 mg/l), activated protein C resistance (act prot C
res, with exception of patients on oral anticoagulation)
(normal value ,2) were analysed upon admission the
day before the surgery.
There were 27 women and 59 men, aged 40–88
years (mean 69 years). Risk factors, as listed in Table 1,
were defined as follows: hypertension when medically
treated, diabetes mellitus types I and II, renal impair-
ment when values of serum-creatinine, exceeded
125 mmol/l and chronic obstructive pulmonary dis-
ease (COPD) when receiving continuously or period-
ically medication for that condition. Smokers were
classified as such when still smoking or having
smoked within the last 5 years. The indications for
operation are listed in Table 2. All but one case had
stenoses of$70%. In one case the indication was a 60–
70% symptomatic stenosis. Post-operative follow-up
was done at 1, 3, 6, 9, 12 and 18 months and yearly
thereafter with clinical assessment and triplex ultra-
sound. The median follow-up time was 17 months
(range 9–42 months). Residual stenosis was recorded
as being present when a stenotic area was noted at the
proximal or distal end of the endarterectomized site at
30-day follow-up. The identification of restenosis was
made only if the abnormality became apparent
subsequent to a normal 30-day triplex ultrasound
assessment. The presence of an at least 50% restenosis
was determined if systolic flow-ratio (internal carotid
artery/common carotid artery flow velocity) was.1.5
and internal carotid systolic peak velocity was
.120 cm/s with an end diastolic velocity .40 cm/
s.17 Patients suspected of postoperative complications
as TIA or stroke underwent a neurological
examination.
All data were censored at the date of last follow-up.
The presence of a restenosis $50% was considered an
event. Calculations of factors with respect to restenosis
rates were done on basis of treated carotid arteries.
All data were prospectively registered in a vascular
registry run by the department and analysed with
SPSS 10.0.7 for Windows. Freedom from restenosis
rates were estimated and illustrated with the Kaplan–
Meier method,18 using the log-rank test for compari-
son of groups.19 The influence of plasma homocysteine
levels on time to endpoint occurrence (restenosis) was
evaluated from the standpoint of the high versus low
levels in a stepwise manner by division into groups of
1/3. The cut-off point of the lower 1/3 of the
homocysteine level in the study population was
found to be 10 mmol/l. A ROC-curve analysis of
homocysteine values versus restenosis deemed a
homocysteine value of 10.1 mmol/l as the point with
the highest additive value of sensitivity and specificity
ðp ¼ 0:044Þ: Multivariate analysis adjusting for age,
gender and risk factors was performed with Cox
proportional hazards model.20 Comparison of con-
tinuous variables between two groups was done with
Student’s t-test and more than two groups was done
with one way analysis of variance (ANOVA). p-Values
below 0.05 were accepted as significant.
Results
Eleven of 96 cases (11%) progressed to restenosis but
none to reocclusion. So far none of the restenoses have
Table 1. Risk factors in 86 patients subjected to 96 carotid
endarterectomies
Risk factor Number of patients (%)
Ischaemic heart disease 41 47
Hypertension 39 45
Diabetes mellitus 9 10
COPD 9 10
Smoker 47 49
Se-creatinine .125 mmol/l 14 16
COPD, chronic obstructive pulmonary disease.
Table 2. Indication for operation of 96 internal carotid stenoses in
86 patients
Indication n %
Asymptomatic .70% 10 10
Amaurosis fugax 19 20
TIA 34 35
Stroke 33 35
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been symptomatic, demanding reoperation or reinter-
vention. The median time from operation to diagnosis
of restenosis was 8 months (range 5–17 months). The
patients who suffered restenosis were younger (mean
64 years) than the patients who did not (mean 70
years), but this difference was not statistically
significant.
Comparison of cases with and without restenosis
(log-rank test) with respect to risk factors, plasma
parameters, symptoms and degree of affection of the
precerebral circulation (graded as 1, 2, 3 or 4 arteries
affected by significant stenoses or occlusions as seen
on the preoperative angiogram) revealed that the rates
of restenosis in cases with Hcy #10 mmol/l were
significantly higher than in patients with Hcy
.10 mmol/l ðp ¼ 0:0076Þ (Fig. 1). Restenosis rates in
patients free from clinically known ischaemic heart
disease (IHD) were significantly higher compared to
patients with IHD ðp ¼ 0:0059Þ (Fig. 2). Multivariate
analysis adjusting for age, gender and risk factors with
exception of smoking revealed independent signifi-
cant higher restenosis rates in patients with Hcy
#10 mmol/l compared to patients with Hcy
.10 mmol/l ðp ¼ 0:046Þ: The relationship between
freedom from IHD and restenosis rates was not
found to be significant on multivariate analysis ðp ¼
0:051Þ: Plasma values of Fibr, D-dim or presence of act
prot C res was not significantly associated with
restenosis rates. Neither were any of the other risk
factors listed in Table 1.
Mean values of Hcy, Fibr, D-dim and activated
protein C resistance were not significantly associated
with symptoms (classified into three categories as
asymptomatic, stroke, tia or amaurosis fugax). Com-
parison of mean values of Hcy, Fibr and D-dim with
respect to affection of the precerebral circulation
(classified as 1, 2, 3 or 4 precerebral arteries affected
either by significant stenoses or occlusion(s) as seen on
the pre-operative angiogram) revealed no differences
of statistical significance between the groups.
Discussion
The relationship between elevated homocysteine
concentrations and atherosclerosis were first observed
by McCully in patients with homocysteinuria, a
metabolic deficiency resulting from an autosomal
recessive error, most commonly due to a cystathionine
b syntethase deficiency.21 Homozygotes are more
severely affected than heterozygotes and may be
categorized according to responsiveness to sup-
plementation therapy with vitamins B6, B12 or
folate.22 Mild hyperhomocysteinemia can be caused
by deficiency of the aforementioned vitamins, but the
implications of supplement therapy are yet
unsettled.23 – 30 The relationship between elevated
homocysteine and cardiovascular, cerebrovascular as
well as peripheral vascular atherosclerosis has been
demonstrated. But the role of homocysteine in
vascular disease, as a causative factor or an indicator,
has not been clarified.31 – 39 Cell culture and animal
model experiments have elucidated several potential
mechanisms by which hyperhomocysteinemia may
stimulate myointimal hyperplasia: inhibition of endo-
thelial cell proliferation and stimulation of vascular
smooth cell growth,40,41 endothelial cell damage by
generation of free radicals42 combined with destruc-
tion of endothelial cell protective mechanisms such as
nitric oxide and glutathione.43,44 Furthermore, homo-
cysteine has been found to cause a decrease in
compounds potentially inhibiting vascular smooth
muscle proliferation,45 and to create a procoagulant
milieu through modulation of the coagulation and
fibrinolytic pathway.46 – 49 The nitride oxide depressing
mechanism of homocysteine has been linked to an
inhibition of endothelium-dependent vasodilatation
found in vivo and in vitro studies.50,51
The causal relationship between restenosis and
elevated homocysteine has not been determined.
Only two studies of five on the effect of hyperhomo-
cysteinemia on the results of peripheral vascular
interventions have demonstrated a significant
relationship between failure and levels of homocys-
teine.13 – 16,52
Fig. 1. Comparison of cumulated rates of freedom from
restenosis (log-rank) of 96 carotid endarterectomies in
patients with plasma homocysteine values #10 mmol/l†
and .10 mmol/l*. The numbers below the curve indicate
patients at risk.
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Hyperhomocysteinemia is found to increase intimal
hyperplasia in rat carotid endarterectomy model,53
suppressible by folate supplementation.54 In a group
of 287 pairs of adults asymptomatic of atherosclerosis,
Malinow et al. found that subjects with increased
intimal-medial thickness of the carotid wall had
significantly higher plasma homocysteine levels than
controls.7 Selhub et al. found in a cross-sectional study
of 1041 subjects an odds-ratio for carotid stenosis
$25% of 2.0 for subjects with the highest plasma
homocysteine concentrations as compared with those
with the lowest concentrations.34 In the ‘Homocysteine
and Progression of Atherosclerosis Study’, Taylor et al.
followed 351 subjects with known atherosclerotic
disease in a mean period of 37 months. Deaths from
any cause as well as from cardiovascular disease were
significantly more likely in subjects with the highest
33% of plasma homocysteine levels compared to those
with the lowest 33%. The subjects with the highest
levels of homocysteine were significantly more likely
to have non-fatal clinical progression of coronary heart
disease. However, there was no progression of
cerebro-vascular disease related to homocysteine
levels as assessed by increasing carotid stenosis.8
Until now, there exist no publications on the relation-
ship between homocysteine and restenosis or reocclu-
sions after carotid endarterectomy in humans.
In our study, hyperhomocysteinemia did not
increase the risk of restenosis after carotid endarter-
ectomy. On the contrary, we found a significant and
independent association between values in the lower
two-thirds of the normal range (the lowest 1/3 of the
range of homocysteine in the study population) and
the tendency to restenosis. Freedom from clinically
known ischaemic heart disease was also a significant,
but dependent, predictor of restenosis. Homocysteine
levels could neither be related to symptoms nor the
degree of atherosclerosis in the precerebral circulation.
Our findings suggest that the process of restenosis
after carotid endarterectomy possibly differs from the
process of atherosclerosis related to or induced by
hyperhomocysteinemia in some respect. If so, it may
be that the process of restenosis in endarterectomized
arteries is basically different from the one seen after
endovascular interventions: In the endarterectomized
artery that of aggravated trauma response or inflam-
matory reaction to a sectional removal of intima and
exposure of the media to circulating blood. In arteries
traumatized by balloon angioplasty, that of intimal
damage resulting creation of clots adhering to the
traumatized site, triggering or aggravating an ongoing
process of atherosclerosis. The biological properties of
the human carotid endothelium can perhaps provide
an explanation for the result. It is known that the
extrinsic properties of endothelial cells can vary
depending on their location. An example is the
heterogeneous distribution of von Willebrand factor
and von Willebrand factor propeptide in the porcine
vascular tree.55 One can hypothesize that the biological
effect of homocysteine on endothelial cells may
depend on their localization.
Our results state rather the opposite of the expected,
why the results must be interpreted with appropriate
caution. The material is small with a relatively short
follow-up time. However, it seems that the majority of
the restenosis develop within the first two years of the
operation. Studies on the biological properties of
human endothelial cells from different types of
vasculature and different locations, with respect to
homocysteine metabolism, different types of arterial
trauma and their effect, are warranted.
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Fig. 2. Comparison of cumulated rates of freedom from
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(unbroken line) and without ischaemic heart disease (broken
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